At a glance
- Originator Uriach
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 21 Dec 2001 Discontinued-Preclinical for Thrombosis in Spain (Unknown route)
- 14 Sep 1998 New profile
- 14 Sep 1998 Preclinical development for Thrombosis in Spain (Unknown route)